Company intelligence / Profile preview

GlycoAla

London, United Kingdom

Ownership: Private
Development stage: Other

Overview

GlycoAla is an aesthetic biotechnology company specializing in advanced photodynamic therapy (PDT) for skin rejuvenation and dermatological conditions. The company's flagship product is a unique, light-activated cosmetic gel that utilizes a glycoconjugated form of 5-aminolevulinic acid (5-ALA) encapsulated in nanoparticles. This proprietary delivery system is designed to enhance skin absorption and stability while minimizing the side effects typically associated with traditional PDT. GlycoAla's treatments are used by skincare professionals to address signs of aging, sun damage, and pore appearance, positioning the company at the intersection of medical aesthetics and biotechnology.

Therapeutic areas: NephrologyDermatology
Modalities: Small moleculeNanoparticlePhotodynamic therapy
Industry: Non-Drug Biotech

Beyond the preview

Go deeper on GlycoAla.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GlycoAla.

Explore the full profile